PMID- 35718990
OWN - NLM
STAT- MEDLINE
DCOM- 20220621
LR  - 20240102
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 28
DP  - 2022 Jun 20
TI  - A Single-Center Retrospective Study to Compare the Efficacy and Safety of 
      Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with 
      Resected Pancreatic Carcinoma.
PG  - e937136
LID - 10.12659/MSM.937136 [doi]
AB  - BACKGROUND Studies are ongoing to determine the optimal adjuvant chemotherapy 
      (ACT) for resected pancreatic carcinoma (PC). FOLFIRINOX is a chemotherapy 
      regimen including oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil (5-FU). 
      S-1 is a fluoropyrimidine derivative widely used as ACT for gastrointestinal 
      malignancy. This single-center retrospective study aimed to compare the efficacy 
      and safety of modified FOLFIRINOX (mFOLFIRINOX) with S-1 as ACT for resected PC. 
      MATERIAL AND METHODS A total of 71 patients with PC who accepted ACT after R0 
      resection between February 2016 and January 2019 were enrolled in this 
      retrospective study. Among these patients, 34 received mFOLFIRINOX regimen 
      chemotherapy (mFFX group), while 37 received S-1 monochemotherapy (S-1 group). 
      The mFOLFIRINOX regimen included oxaliplatin 65 mg/m(2), leucovorin 400 mg/m(2), 
      irinotecan 150 mg/m(2), 5-FU 400 mg/m(2), and continuous 5-FU 2400 mg/m(2) (for 46 h), 
      in a 2-week schedule. The S-1 monochemotherapy (80-120 mg/day according to body 
      surface area [BSA], in 2 divided doses for 2 week) was administrated every 3 
      weeks. We followed up these patients and analyzed the relapse-free survival 
      (RFS), overall survival (OS), and chemotherapy-induced adverse events (AEs). 
      RESULTS The mFFX group demonstrated a markedly higher 3-year RFS (P=0.0332) and 
      OS (P=0.0346) than the S-1 group. Patients in the mFFX group experienced 
      significantly more common and severe thrombocytopenia (P=0.0372), fatigue 
      (P=0.0226), nausea/vomiting (P=0.0337), and diarrhea (P=0.0018). No 
      chemotherapy-induced death was documented. CONCLUSIONS This retrospective study 
      indicated that if dose adjustment and adverse events management are properly 
      administrated, mFOLFIRINOX regimen chemotherapy could result in an improved 
      survival compared with S-1 monochemotherapy for resected PC.
FAU - Yao, Linhua
AU  - Yao L
AD  - Department of Gastroenterology, First People's Hospital Affiliated with Huzhou 
      Normal College, Huzohu, Zhejiang, China (mainland).
FAU - Tang, Chengwu
AU  - Tang C
AD  - Department of General Surgery, First People's Hospital Affiliated with Huzhou 
      Normal College, Huzhou, Zhejiang, China (mainland).
FAU - Feng, Wenming
AU  - Feng W
AD  - Department of General Surgery, First People's Hospital Affiliated with Huzhou 
      Normal College, Huzhou, Zhejiang, China (mainland).
FAU - Dai, Hanbin
AU  - Dai H
AD  - Department of General Surgery, First People's Hospital Affiliated with Huzhou 
      Normal College, Huzhou, Zhejiang, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20220620
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (folfirinox)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 7673326042 (Irinotecan)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Chemotherapy, Adjuvant
MH  - Fluorouracil/adverse effects
MH  - Humans
MH  - Irinotecan/therapeutic use
MH  - Leucovorin/adverse effects
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Oxaliplatin/therapeutic use
MH  - *Pancreatic Neoplasms/drug therapy/surgery
MH  - Retrospective Studies
PMC - PMC9229892
COIS- Conflict of interest: None declared
EDAT- 2022/06/21 06:00
MHDA- 2022/06/22 06:00
PMCR- 2022/06/20
CRDT- 2022/06/20 01:22
PHST- 2022/06/20 01:22 [entrez]
PHST- 2022/06/21 06:00 [pubmed]
PHST- 2022/06/22 06:00 [medline]
PHST- 2022/06/20 00:00 [pmc-release]
AID - 937136 [pii]
AID - 10.12659/MSM.937136 [doi]
PST - epublish
SO  - Med Sci Monit. 2022 Jun 20;28:e937136. doi: 10.12659/MSM.937136.